Medicare Pays 22% More For Biosimilar Inflectra Than Reference Biologic

Medicare pays 22 percent more for the biosimilar Inflectra than for that of its reference product Remicade, according to congressional Medicare advisers. Inflectra's high list price is an example of why the Medicare Payment Advisory Commission is considering recommending that biosimilars and the biologics they reference be combined in common billing codes to drive down the price of both products. Commissioners also are considering cuts to the rate that physicians are paid to administer drugs immediately after they come to...